144 related articles for article (PubMed ID: 35570522)
1. The Glutaminase Inhibitor Compound 968 Exhibits Potent
Guo H; Li W; Pan G; Wang C; Li D; Liu N; Sheng X; Yuan L
Anticancer Agents Med Chem; 2023; 23(2):210-221. PubMed ID: 35570522
[TBL] [Abstract][Full Text] [Related]
2. Combination effects of paclitaxel with signaling inhibitors in endometrial cancer cells.
Xu C; Li X; Li T; Wang X; Yang Y; Xiao L; Shen H
Asian Pac J Cancer Prev; 2011; 12(11):2951-7. PubMed ID: 22393970
[TBL] [Abstract][Full Text] [Related]
3. Antitumor effect of XCT790, an ERRα inverse agonist, on ERα-negative endometrial cancer cells.
Kokabu T; Mori T; Matsushima H; Yoriki K; Kataoka H; Tarumi Y; Kitawaki J
Cell Oncol (Dordr); 2019 Apr; 42(2):223-235. PubMed ID: 30706380
[TBL] [Abstract][Full Text] [Related]
4. Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway.
Hanna RK; Zhou C; Malloy KM; Sun L; Zhong Y; Gehrig PA; Bae-Jump VL
Gynecol Oncol; 2012 May; 125(2):458-69. PubMed ID: 22252099
[TBL] [Abstract][Full Text] [Related]
5. miR-205 inhibits cell growth by targeting AKT-mTOR signaling in progesterone-resistant endometrial cancer Ishikawa cells.
Zhuo Z; Yu H
Oncotarget; 2017 Apr; 8(17):28042-28051. PubMed ID: 28427207
[TBL] [Abstract][Full Text] [Related]
6. Ipatasertib exhibits anti‑tumorigenic effects and enhances sensitivity to paclitaxel in endometrial cancer
O'Donnell J; Zhao Z; Buckingham L; Hao T; Suo H; Zhang X; Fan Y; John C; Deng B; Shen X; Sun W; Secord AA; Zhou C; Bae-Jump VL
Int J Oncol; 2023 Sep; 63(3):. PubMed ID: 37503790
[TBL] [Abstract][Full Text] [Related]
7. Fucoxanthin prevents cell growth and induces apoptosis in endometrial cancer HEC-1A cells by the inhibition of the PI3K/Akt/mTOR pathway.
Qu J; Sun Y; Yang L; Niu X; Li L
J Biochem Mol Toxicol; 2022 Jun; 36(6):e23027. PubMed ID: 35266250
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel suppresses proliferation and induces apoptosis through regulation of ROS and the AKT/MAPK signaling pathway in canine mammary gland tumor cells.
Ren X; Zhao B; Chang H; Xiao M; Wu Y; Liu Y
Mol Med Rep; 2018 Jun; 17(6):8289-8299. PubMed ID: 29658576
[TBL] [Abstract][Full Text] [Related]
9. Glutaminase inhibitor compound 968 inhibits cell proliferation and sensitizes paclitaxel in ovarian cancer.
Yuan L; Sheng X; Clark LH; Zhang L; Guo H; Jones HM; Willson AK; Gehrig PA; Zhou C; Bae-Jump VL
Am J Transl Res; 2016; 8(10):4265-4277. PubMed ID: 27830010
[TBL] [Abstract][Full Text] [Related]
10. GLS1 promotes proliferation in hepatocellular carcinoma cells via AKT/GSK3β/CyclinD1 pathway.
Xi J; Sun Y; Zhang M; Fa Z; Wan Y; Min Z; Xu H; Xu C; Tang J
Exp Cell Res; 2019 Aug; 381(1):1-9. PubMed ID: 31054856
[TBL] [Abstract][Full Text] [Related]
11. Simvastatin, an HMG-CoA reductase inhibitor, exhibits anti-metastatic and anti-tumorigenic effects in endometrial cancer.
Schointuch MN; Gilliam TP; Stine JE; Han X; Zhou C; Gehrig PA; Kim K; Bae-Jump VL
Gynecol Oncol; 2014 Aug; 134(2):346-55. PubMed ID: 24880141
[TBL] [Abstract][Full Text] [Related]
12. EGFR- and AKT-mediated reduction in PTEN expression contributes to tyrphostin resistance and is reversed by mTOR inhibition in endometrial cancer cells.
Li T; Yang Y; Li X; Xu C; Meng L
Mol Cell Biochem; 2012 Feb; 361(1-2):19-29. PubMed ID: 21952748
[TBL] [Abstract][Full Text] [Related]
13. Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models.
Schrauwen S; Depreeuw J; Coenegrachts L; Hermans E; Lambrechts D; Amant F
Gynecol Oncol; 2015 Jul; 138(1):165-73. PubMed ID: 25933683
[TBL] [Abstract][Full Text] [Related]
14. Study on Biological Characteristics and Mechanism of Paclitaxel Induced Drug Resistance in Endometrial Carcinoma Cells.
Ding J; Li M; Deng L; Li T
Biomed Res Int; 2018; 2018():8372085. PubMed ID: 30175145
[TBL] [Abstract][Full Text] [Related]
15. Rapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of apoptosis.
Shafer A; Zhou C; Gehrig PA; Boggess JF; Bae-Jump VL
Int J Cancer; 2010 Mar; 126(5):1144-54. PubMed ID: 19688827
[TBL] [Abstract][Full Text] [Related]
16. Down-Regulation of the Mammalian Target of Rapamycin (mTOR) Pathway Mediates the Effects of the Paeonol-Platinum(II) Complex in Human Thyroid Carcinoma Cells and Mouse SW1736 Tumor Xenografts.
He L; Guo S; Zhu T; Chen C; Xu K
Med Sci Monit; 2020 Jun; 26():e922561. PubMed ID: 32594094
[TBL] [Abstract][Full Text] [Related]
17. Glucose promotes cell proliferation, glucose uptake and invasion in endometrial cancer cells via AMPK/mTOR/S6 and MAPK signaling.
Han J; Zhang L; Guo H; Wysham WZ; Roque DR; Willson AK; Sheng X; Zhou C; Bae-Jump VL
Gynecol Oncol; 2015 Sep; 138(3):668-75. PubMed ID: 26135947
[TBL] [Abstract][Full Text] [Related]
18. Glutamine promotes ovarian cancer cell proliferation through the mTOR/S6 pathway.
Yuan L; Sheng X; Willson AK; Roque DR; Stine JE; Guo H; Jones HM; Zhou C; Bae-Jump VL
Endocr Relat Cancer; 2015 Aug; 22(4):577-91. PubMed ID: 26045471
[TBL] [Abstract][Full Text] [Related]
19. Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.
Shoji K; Oda K; Kashiyama T; Ikeda Y; Nakagawa S; Sone K; Miyamoto Y; Hiraike H; Tanikawa M; Miyasaka A; Koso T; Matsumoto Y; Wada-Hiraike O; Kawana K; Kuramoto H; McCormick F; Aburatani H; Yano T; Kozuma S; Taketani Y
PLoS One; 2012; 7(5):e37431. PubMed ID: 22662154
[TBL] [Abstract][Full Text] [Related]
20. Effects of Fatty Acid Synthase Inhibition by Orlistat on Proliferation of Endometrial Cancer Cell Lines.
Wysham WZ; Roque DR; Han J; Zhang L; Guo H; Gehrig PA; Zhou C; Bae-Jump VL
Target Oncol; 2016 Dec; 11(6):763-769. PubMed ID: 27188391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
